ELISA Kit for Salusin Beta (SALb) Homo sapiens (Human) Competition ELISA

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • ELISA Kit for Salusin Beta (SALb) Packages (Simulation)
  • ELISA Kit for Salusin Beta (SALb) Packages (Simulation)
  • ELISA Kit for Salusin Beta (SALb) Results demonstration
  • CEC026Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Salusin Beta (SALb) and the recovery rates were calculated by comparing the measured value to the expected amount of Salusin Beta (SALb) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 85-101 97
EDTA plasma(n=5) 92-101 97
heparin plasma(n=5) 98-105 101

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Salusin Beta (SALb) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Salusin Beta (SALb) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Salusin Beta (SALb) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 87-95% 88-95% 78-96% 81-101%
EDTA plasma(n=5) 90-97% 98-105% 82-96% 92-104%
heparin plasma(n=5) 79-92% 98-105% 82-97% 92-99%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1 Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Reagent Diluent 1×300µL Stop Solution 1×6mL
TMB Substrate 1×9mL Instruction manual 1
Wash Buffer (30 × concentrate) 1×20mL

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 50µL standard or sample to each well.
    And then add 50µL prepared Detection Reagent A immediately.
    Shake and mix. Incubate 1 hour at 37°C;
3. Aspirate and wash 3 times;
4. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
5. Aspirate and wash 5 times;
6. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
7. Add 50µL Stop Solution. Read at 450 nm immediately.

ELISA Kit for Salusin Beta (SALb)

Test principle

This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Salusin Beta (SALb) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Salusin Beta (SALb) and unlabeled Salusin Beta (SALb) (Standards or samples) with the pre-coated antibody specific to Salusin Beta (SALb). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Salusin Beta (SALb) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Salusin Beta (SALb) in the sample.

Citations

  • Serum levels of apelin, salusin-alpha, and salusin-beta in normal pregnancy and preeclampsiaInforma: 14767058.2012.660221
  • The bioactive peptides salusins and apelin–36 are produced in human arterial and venous tissues and the changes of their levels during cardiopulmonary bypassPubMed: 22884920
  • Presence of adropin, nesfatin-1, apelin-12, ghrelins and salusins peptides in the milk, cheese whey and plasma of dairy cowsScienceDirect: S0196978113000533
  • Association of low maternal levels of salusins with gestational diabetes mellitus and with small-for-gestational-age fetuses.PubMed: 23178004
  • Serum concentration and kidney expression of salusin-α and salusin-β in rats with metabolic syndrome induced by fructose.PubMed: 23244237
  • Salusins, newly identified regulators of hemodynamics and mitogenesis, increase in polycystic ovarian syndrome.PubMed: 22827297
  • Concentrations of preptin, salusins and hepcidins in plasma and milk of lactating women with or without gestational diabetes mellitusScienceDirect: S0196978113003100
  • Salusin-alpha and -beta expression in heart and aorta with and without metabolic syndrome Com:Source
  • Brain, Liver, and Serum Salusin-alpha and-beta Alterations in Sprague-Dawley Rats with or Without Metabolic SyndromePubmed:Pmc4136931
  • Superoxide anions involved in sympathoexcitation and pressor effects of salusin-β in paraventricular nucleus in hypertensive ratsPubmed:24304512
  • Is the serum level of salusin-β associated with hypertension and atherosclerosis in the pediatric population?Pubmed:25245503
  • Serum salusin-α and salusin-β levels in patients with psoriasisPubMed: 26055619
  • Serum Salusin-β Levels Are Associated With the Presence and Severity of Coronary Artery DiseasePubMed: 25730454
  • Serum Salusin-β Levels Are Correlated with Slow Coronary Flow.Pubmed:27227272
  • Silencing salusin-β attenuates cardiovascular remodeling and hypertension in spontaneously hypertensive rats.pubmed:28230187
  • Salusin-β contributes to oxidative stress and inflammation in diabetic cardiomyopathypubmed:28333148
  • Salusin-β Is Involved in Diabetes Mellitus-Induced Endothelial Dysfunction via Degradation of Peroxisome Proliferator-Activated Receptor Gamma10.1155:2017
  • Silencing salusin β ameliorates heart failure in aged spontaneously hypertensive rats by ROS-relative MAPK/NF-κB pathways in the paraventricular nucleusPubmed: 30581101
  • Increased level of Plasma Salusin-α and Salusin-β in patients with Multiple SclerosisPubmed: 30738876
  • Salusin-α levels are negatively correlated with diastolic blood pressure in children with obesityPubmed: 31486354
  • Salusin-β mediates tubular cell apoptosis in acute kidney injury: Involvement of the PKC/ROS signaling pathwayPubmed: 31884071
  • Salusin-β is superior to salusin-α as a marker for evaluating coronary atherosclerosisPubmed: 32054363
  • A TOR2A Gene Product: Salusin-β Contributes to Attenuated Vasodilatation of Spontaneously Hypertensive Rats.Pubmed: 32458319
  • Serum level of salusin β as an indicator of metabolic disorders in Acute Lymphoblastic Leucaemia and Wilms Tumour survivors
  • Salusin‑β participates in high glucose‑induced HK‑2 cell ferroptosis in a Nrf‑2‑dependent manner34296310

Recommend products